[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Tomoo
Takashi
T
takashi.tomoo@novartis.com
Suzuki
Masayuki
M
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy; D002117:Calcitriol / Q000037:antagonists & inhibitors; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D051228:Geranyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology*; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications*; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D051228:Geranyltranstransferase; D002117:Calcitriol